论文部分内容阅读
目的探讨替吉奥一线治疗老年晚期胰腺癌的临床疗效及安全性。方法选取病理证实的老年(65~81岁)晚期胰腺癌患者29例,一线给予替吉奥单药化疗,体表面积<1.25 m2时给予40mg Bid,1.25~1.5 m2时给予50 mg Bid,体表面积≥1.5 m2时给予60 mg Bid d1-14口服,每3周重复,每2个周期后行CT检查评价疗效及不良反应,化疗有效患者最多至6周期结束。结果 29例患者均完成替吉奥单药一线治疗,其中完全缓解CR 0例,部分缓解PR 6例(20.7%),稳定SD11例(37.9%),进展PD12例(41.4%),中位疾病进展时间TTP 3.7个月(2.9~6.1个月),中位生存期8.5个月(6.9~10.9个月),毒副反应以骨髓抑制,消化道反应为主,未出现IV度化疗副反应,其中中性粒细胞减少10例,贫血4例,恶心呕吐8例,厌食2例,乏力3例。结论替吉奥单药作为一线治疗老年晚期胰腺癌疗效好,且安全、毒副反应轻,患者耐受性好,对于高龄及生活质量评分相对偏低的患者是较好的选择。
Objective To investigate the clinical efficacy and safety of Tiagio for the treatment of advanced pancreatic cancer in elderly patients. Methods Twenty-nine patients with pathologically confirmed advanced pancreatic cancer (aged 65-81 years) were enrolled in this study. The first-line chemotherapy was given for the treatment of getigmine alone. When the body surface area was less than 1.25 m2, 40 mg bid and 1.25 mg / ≥1.5 m2 were given 60 mg Bid d1-14 orally, repeated every 3 weeks, CT scan after 2 cycles to evaluate the efficacy and adverse reactions, the effective chemotherapy patients up to 6 cycles. Results Twenty-nine patients were treated with first-line treatment of tioguanide alone, including complete remission of CR 0, partial remission of PR 6 cases (20.7%), stable SD 11 cases (37.9%), progression of PD 12 cases (41.4% The duration of TTP was 3.7 months (range, 2.9 to 6.1 months), and the median survival time was 8.5 months (range, 6.9-10.9 months). The side effects were bone marrow suppression and digestive tract reaction. Including neutropenia in 10 cases, 4 cases of anemia, nausea and vomiting in 8 cases, 2 cases of anorexia, fatigue in 3 cases. Conclusion As a first-line treatment for elderly patients with advanced pancreatic cancer, the single-agent treatment of getiao is effective, safe, light toxic and side tolerant, and is a good choice for patients with advanced age and relatively low quality of life score.